Targeted Oncology2d
FDA Oks Optune Lua for Use With PD-1/PD-L1 Inhibitors in Metastatic NSCLC
Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...
EurekAlert!17d
FOXM1 and PD-L1 in CDK4/6-MEK resistance in nerve tumors
A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, “Linking FOXM1 and PD-L1 to CDK4/6 ...
Cure Today7d
I Still Reflect on My Lung Cancer Treatment Decisions
When I was diagnosed with lung cancer, I didn’t want to receive chemotherapy, especially when I was a good candidate for ...
BioWorld21d
Discovery of PD-L1-degrading PROTACs with promising antitumor efficacy
A new series of proteolytic targeting chimeras (PROTACs) was designed by Zhejiang University of Technology scientists based ...
emjreviews.com3d
New Imaging Technique Shows Promise for Personalised Oesophageal Cancer Treatment – UEG Week 2024
Discover a breakthrough imaging technique aimed at improving treatment outcomes for patients with locally advanced ...
precisionmedicineonline3d
Phase II Trial of Transgene HPV-Targeted Cancer Vaccine Misses Primary Endpoint
Treatment with the vaccine did not improve progression-free survival in patients with HPV16-positive cervical and anogenital tumors.
Armed robbery in Revesby17d
FOXM1, PD-L1 Linked to CDK4/6-MEK Resistance in Nerve Tumors
We suggest that future therapeutic strategies targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 represent ...